Proportion participants that switched to another biologic due to loss of response ‐ not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation leads to higher proportion participants with minimal radiographic progression compared with anti‐TNF continuation (high certainty).
1 finding from 1 review
Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).
1 finding from 1 review
Disease activity · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation may leads to lower proportion of participants with persistent remission compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Discontinuation due to adverse events · Patients with fibromyalgia
It is very uncertain whether the intervention changes discontinuation due to adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Discontinuations due to adverse events · patients with rheumatoid arthritis
The intervention leads to higher discontinuations due to adverse events (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with chronic cout
Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with fibromyalgia
1 finding from 1 review
Intervention not reported
Withdrawal due to adverse events Methotrexate discontinuation · patients with inflammatory arthritis on methotrexate
1 finding from 1 review
Intervention not reported
Discontinuation rates · patients with rheumatoid arthritis
1 finding from 1 review
Disease activity · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review